BMJ19h
Update of EULAR recommendations for the treatment of systemic sclerosis
The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. Update of the ...
BMJ5d
2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome
Objectives To develop and validate an international set of classification criteria for primary Sjögren's syndrome (SS) using guidelines from the American College of Rheumatology (ACR) and the European ...
BMJ6d
Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
Objective This observational cohort study investigated the impact of biological (b) disease-modifying antirheumatic drugs (DMARDs) on the outcomes of serious infections (SIs) in patients with ...
BMJ9d
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
7 CIRI/Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Fraunhofer Cluster of Excellence for Immune-Mediated Disease (CIMD), Goethe University, Frankfurt, ...
BMJ10d
Settings and artefacts relevant in colour/power Doppler ultrasound in rheumatology
The Parker Institute, Frederiksberg Hospital, Copenhagen University Hospital, The Capital Region of Denmark, DK-2000 Copenhagen F, Denmark Søren Torp-Pedersen, The Parker Institute, Frederiksberg ...
BMJ13d
Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study
1 Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Denmark 2 Department of Rheumatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark 3 Department of ...
BMJ13d
Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017
Objectives To report the level and trends of prevalence, incidence and years lived with disability (YLDs) for osteoarthritis (OA) in 195 countries and territories from 1990 to 2017 by age, sex and ...
BMJ15d
L-arginine metabolism inhibits arthritis and inflammatory bone loss
Objectives To investigate the effect of the L-arginine metabolism on arthritis and inflammation-mediated bone loss. Methods L-arginine was applied to three arthritis models (collagen-induced arthritis ...
BMJ15d
Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)
Objectives In the complex panorama of autoimmune diseases, the characterisation of pivotal contributing autoantibodies that are involved in disease progression remains challenging. This study aimed to ...
BMJ16d
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Objectives Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in ...
BMJ16d
Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis
Objectives Metabolic changes are crucially involved in osteoclast development and may contribute to bone degradation in rheumatoid arthritis (RA). The enzyme aconitate decarboxylase 1 (Acod1) is known ...
BMJ19d
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...